TruMerit Launches Global Credential for First-Level, General Nurses TruMerit Aug 06, 2025 09:00 HKT/SGT Read More
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
全球首個IgA腎病對因治療藥物耐賦康®擴產獲批 雲頂新耀加速提升可及性與產能佈局 Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
全球首个IgA肾病对因治疗药物耐赋康®扩产获批 云顶新耀加速提升可及性与产能布局 Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
旅行者醫療支援平台 Traveler Care 正式全球上線,協助旅遊保險公司減少 80% 急診索賠 Traveler Care Aug 04, 2025 23:00 HKT/SGT Read More
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80% Traveler Care Aug 04, 2025 21:00 HKT/SGT Read More
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies Everest Medicines Limited Aug 02, 2025 00:02 HKT/SGT Read More
雲頂新耀宣佈增加對I-Mab的戰略投資 開發自研新一代腫瘤免疫療法的全球價值 Everest Medicines Limited Aug 01, 2025 23:48 HKT/SGT Read More
云顶新耀宣布增加对I-Mab的战略投资 开发自研新一代肿瘤免疫疗法的全球价值 Everest Medicines Limited Aug 01, 2025 23:45 HKT/SGT Read More
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Jul 31, 2025 08:30 HKT/SGT Read More
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease Eisai Jul 31, 2025 08:20 HKT/SGT Read More
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 Eisai Jul 31, 2025 08:10 HKT/SGT Read More
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma Eisai Jul 29, 2025 08:01 HKT/SGT Read More
GEN 與 Sulfateq BV 公佈治療阿茲海默症及其他神經退化性疾病的候選藥物 SUL-238 的第一階段臨床試驗正面結果 GEN Pharmaceuticals Jul 29, 2025 08:00 HKT/SGT Read More
GEN 与 Sulfateq BV 公布治疗阿尔茨海默病及其他神经退行性疾病的候选药物 SUL-238 的第一阶段临床试验积极结果 GEN Pharmaceuticals Jul 29, 2025 08:00 HKT/SGT Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 05:00 JST Read More
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China China Medical System Holdings Limited Jul 29, 2025 04:00 HKT/SGT Read More
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases GEN Pharmaceuticals Jul 28, 2025 20:00 HKT/SGT Read More